Lovly CM. New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years. J Clin Oncol 2024 Sep 4:JCO2401147. doi: 10.1200/JCO.24.01147.
PMID: 39231392